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Introduction
============

Community acquired pneumonia, one of the leading infectious diseases in more economically developed countries, is associated with considerable morbidity and mortality. The pulmonary infection itself but also its associated, especially systemic, inflammatory response, playing a major part in these outcomes.[@ref1] Any condition that increases susceptibility to infection and predisposes to severe disease may have an impact on outcome. Diabetes mellitus is linked to impaired immunity and has to be considered a predisposing factor for a wide variety of infectious diseases, including pneumonia.[@ref2] [@ref3] [@ref4] Up to 25% of patients with community acquired pneumonia have diabetes.[@ref5] Above all, there is a clear association between diabetes and cardiovascular disease and stroke, both major contributors to complications of community acquired pneumonia.[@ref1] [@ref6] [@ref7] [@ref8] A plethora of diabetes associated conditions such as an increased risk of aspiration, decreased immunity, impaired lung function, and pulmonary microangiopathy, are assumed to link diabetes and community acquired pneumonia.[@ref9] It is plausible that chronic hyperglycaemia in itself influences a variety of host defence functions, such as chemotaxis, phagocytosis, and bactericidal activity of histiocytic cells. Nevertheless it has been shown that intensive insulin therapy to correct the metabolic status of patients admitted to hospital has no evident effect on infections or overall mortality.[@ref10]

Recent, mainly retrospective studies, suggested that pre-existing diabetes or alterations to glucose serum levels are associated with an increased length of hospital stay or higher mortality due to infections, including community acquired pneumonia, but others showed no or no clear association.[@ref11] [@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] Some of the previous studies, showing an association between diabetes and admission to hospital, might be confounded by a high prevalence of underlying comorbidities and selective patient recruitment.[@ref13] [@ref16]

Given the strong association between diabetes and cardiovascular disease that contributes to overall mortality from community acquired pneumonia and infection and acute, illness related hyperglycaemia, we tested the hypothesis that glucose serum levels on admission and pre-existent diabetes are associated with mortality in patients admitted to hospital for community acquired pneumonia.

Methods
=======

We carried out a multicentre study using prospective data from the German collaborative network on community acquired pneumonia (CAPNETZ).[@ref19] All participants gave informed consent. Data were collected based on a standard protocol, starting in July 2002, and analysed in December 2009. We included adults presenting with a new pulmonary infiltrate on a chest radiograph together with at least one symptom or sign of lower respiratory tract infection (fever, cough, purulent sputum, focal chest signs). Exclusion criteria were hospital admission within the past 28 days; immunosuppression, defined as chemotherapy or neutropenia \<1000 μL during the past 28 days; treatment with more than 20 mg corticosteroids daily for longer than 14 days; HIV infection; immunosuppressive therapy after organ or bone marrow transplantation; and active tuberculosis. Participants were followed up for six months.

Severity of pneumonia was assessed using the CRB-65 score (confusion, respiratory rate \>30/min, systolic blood pressure ≤90 mm Hg or diastolic blood pressure ≤60 mm Hg, and age ≥65 years).[@ref20] The supplementary appendix provides a description of the study setting, periods of recruitment, eligibility criteria, follow-up, and mode of data collection.

Definitions and measurement of glucose serum levels
---------------------------------------------------

We assessed whether baseline diabetes status (ascertained on the basis of self report or drug use, including long term use of glucose lowering drugs, or a combination of both) and serum glucose levels on admission related to death from community acquired pneumonia within the first 28, 90, and 180 days from diagnosis. Single random glucose concentrations of 11.1 mmol/L (200 mg/dL) or less are formally within the "normal" range[@ref21]; however, for our analysis we defined acute hyperglycaemia as any serum glucose concentration of 6 mmol/L or more measured on admission. Additionally, we a priori defined similar, or as in previous studies,[@ref2] [@ref16] [@ref17] [@ref22] categories for serum glucose concentration of \<4 mmol/L (72 mg/dL), 4-5.99 mmol/L (108 mg/dL), 6-10.99 mmol/L (198 mg/dL), 11-13.99 mmol/L (252 mg/dL), and ≥14 mmol/L (252 mg/dL).

Statistical analysis
--------------------

Using univariable Cox proportional hazards models, and deriving 95% confidence intervals, we examined the associations between baseline characteristics of participants and death from any cause after 90 days and tested associations with two sided Wald tests.

We categorised serum glucose level on admission using prespecified thresholds corresponding to the patients' baseline serum glucose levels at the time of enrolment (that is, admission to hospital). To assess associations between serum glucose levels or diabetes status and mortality after 90 days we used Kaplan-Meier estimates, and to test for linear trends across serum glucose levels we used multivariable Cox proportional hazards models adjusted for sex, CRB-65 score, comorbidities, smoking, and infectious agent. We then stratified the analyses of associations between serum glucose levels and mortality after 90 days according to diabetes status. Finally, using Kaplan-Meier estimates and in crude and adjusted Cox proportional hazards regression analyses we compared mortality after 90 days in participants without diabetes and low or normal serum glucose concentrations (\<6 mmol/L), those without diabetes and increased serum glucose concentrations (≥6 mmol/L), and those with diabetes. In all regression analyses we accounted for missing data on covariates by using multiple imputation, with overall mortality, log transformed survival time, sex, age, smoking, CRB-65 class, comorbidities, serum glucose levels, admission to hospital, and infectious agent as variables in the imputation model, thus creating 20 imputed datasets.[@ref23] [@ref24] We then carried out a case analysis of the 5231 (71%) patients with complete data on outcomes and covariates and sensitivity analyses to examine associations between serum glucose levels or diabetes and mortality up to 28 days and up to 180 days using crude and adjusted Cox proportional hazards models. Then we stratified analyses according to severity of pneumonia using cut-off scores of 1 and 3 points on the CRB-65 to distinguish between mild, moderate, and severe pneumonia and carried out a test for interaction between trends across serum glucose levels and severity of pneumonia. Finally, we carried out landmark analyses with a landmark point at 28 days, with trends across serum glucose levels determined separately for 0 to 28 days and 29 to 90 days, and a test for interaction between trends across serum glucose levels and time (0 to 28 days *v* 29 to 90 days).

All P values and 95% confidence intervals are two sided. Statistical analyses were done with Stata version 11.2 (College Station, TX).

Results
=======

Between 2002 and 2009, 7400 patients with community acquired pneumonia were included in the German community acquired pneumonia competence network (CAPNETZ) registry. Of these, 509 were excluded because of missing information on death, leaving 6891 patients from 12 clinical centres throughout Germany for analysis (see supplementary figure 1). At the time of enrolment, 1114 (16.2%) patients had a diagnosis of diabetes. The mean age of participants was 59.8 (SD 18.5) years and 3805 (55.2%) were men. Table 1[](#tbl1){ref-type="table"} provides an overview of the participants' baseline characteristics and the hazard ratios of death within 90 days of admission for community acquired pneumonia. In total, 4671 (67.8%) participants were treated as inpatients.

###### 

 Baseline characteristics in 6891 patients with community acquired pneumonia and hazard ratio for death within 90 days after admission to hospital

  Characteristics                         Follow-up at 90 days   Hazard ratio\* (95% CI) for complete data   P value                    Hazard ratio\* (95% CI) using multiple imputation†   P value‡              
  --------------------------------------- ---------------------- ------------------------------------------- -------------------------- ---------------------------------------------------- --------------------- ---------
  Sex:                                                                                                                                                                                                             
   Women                                  193 (38)               2893 (45)                                   1.00 (ref)                 0.001                                                1.00 (ref)            0.001
   Men                                    321 (62)               3484 (55)                                   0.74 (0.62 to 0.88)        0.74 (0.62 to 0.88)                                                        
  CRB-65§:                                                                                                                                                                                                         
   0                                      28 (5)                 2433 (38)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   1                                      178 (35)               2335 (37)                                   6.38 (4.28 to 9.50)        6.35 (4.32 to 9.33)                                                        
   2                                      164 (32)               786 (12)                                    16.64 (11.14 to 24.84)     17.25 (11.68 to 25.48)                                                     
   3                                      63 (12)                132 (2)                                     35.40 (22.66 to 55.21)     37.84 (24.77 to 57.81)                                                     
   4                                      15 (3)                 8 (0)                                       100.64 (53.71 to 188.58)   96.71 (52.29 to 178.88)                                                    
  Serum glucose concentration (mmol/L):                                                                                                                                                                            
   \<4                                    17 (3)                 467 (7)                                     0.94 (0.56 to 1.58)        \<0.001                                              0.83 (0.49 to 1.39)   \<0.001
   4-5.99                                 84 (16)                2160 (34)                                   1.00 (ref)                 1.00 (ref)                                                                 
   6-10.99                                281 (55)               2487 (39)                                   2.80 (2.19 to 3.57)        2.89 (2.27 to 3.69)                                                        
   11-13.99                               41 (8)                 262 (4)                                     3.82 (2.63 to 5.55)        4.01 (2.78 to 5.81)                                                        
   ≥14                                    43 (8)                 174 (3)                                     5.91 (4.10 to 8.54)        6.04 (4.18 to 8.74)                                                        
  Diabetes mellitus:                                                                                                                                                                                               
   No                                     351 (69)               5405 (85)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    161 (31)               953 (15)                                    2.48 (2.05 to 2.99)        2.47 (2.05 to 2.98)                                                        
  Chronic respiratory tract disease:                                                                                                                                                                               
   No                                     306 (60)               4088 (65)                                   1.00 (ref)                 0.058                                                1.00 (ref)            0.053
   Yes                                    203 (40)               2263 (35)                                   1.19 (0.99 to 1.42)        1.19 (1.00 to 1.42)                                                        
  Malignant tumour:                                                                                                                                                                                                
   No                                     411 (82)               5793 (91)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    95 (18)                552 (9)                                     2.29 (1.83 to 2.87)        2.29 (1.84 to 2.87)                                                        
  Chronic liver disease:                                                                                                                                                                                           
   No                                     482 (94)               6162 (97)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    29 (6)                 185 (3)                                     1.96 (1.35 to 2.85)        1.97 (1.36 to 2.87)                                                        
  Congestive heart failure:                                                                                                                                                                                        
   No                                     280 (55)               5316 (84)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    230 (45)               1035 (16)                                   3.94 (3.31 to 4.69)        3.95 (3.32 to 4.70)                                                        
  Cerebrovascular disease:                                                                                                                                                                                         
   No                                     326 (64)               5814 (92)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    184 (36)               538 (8)                                     5.39 (4.50 to 6.46)        5.40 (4.51 to 6.47)                                                        
  Chronic renal disease:                                                                                                                                                                                           
   No                                     379 (75)               5912 (93)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    130 (25)               436 (7)                                     4.18 (3.43 to 5.10)        4.18 (3.43 to 5.10)                                                        
  Current smoking:                                                                                                                                                                                                 
   No                                     363 (81)               4293 (68)                                   1.00 (ref)                 \<0.001                                              1.00 (ref)            \<0.001
   Yes                                    87 (19)                1985 (32)                                   1.89 (1.49 to 2.39)        1.86 (1.47 to 2.35)                                                        

749 patients (11%) had missing information on CRB-65 score, 875 (13%) on glucose levels, 21 (0.3%) on diabetes, 31 (0.5%) on chronic respiratory tract disease, 39 (0.6%) on malignant tumour, 33 (0.5%) on chronic liver disease, 30 (0.4%) on congestive heart failure, 29 (0.4%) on cerebrovascular disease, 34 (0.5%) on chronic renal disease, and 163 (2%) on current smoking.

\*From univariable Cox proportional hazards models. Hazard ratios larger than 1 indicate a lower mortality in the reference category.

†Multiple imputation of missing covariate data, including all 6891 participants.

‡Derived from two sided Wald tests.

§Score for confusion, respiratory rate \>30/min, systolic blood pressure ≤90 mm Hg or diastolic blood pressure ≤60 mm Hg, and age ≥65 years.

Admission hyperglycaemia and mortality
--------------------------------------

Overall, 324 (4.7%) participants died within 28 days, 514 (7.5%) within 90 days, and 648 (9.4%) within 180 days. Overall mortality on days 28, 90, and 180 was significantly higher in participants with diabetes than without diabetes (day 90: 14.5% *v* 6.1%; crude hazard ratio 2.47, 95% confidence interval 2.05 to 2.98; P\<0.001). Mortality increased according to CRB-65 score (P\<0.001). Being male and having comorbidities were also associated with increased mortality within 90 days (P\<0.001). Table 1 shows crude associations between mortality within 90 days and patient baseline characteristics.

Higher serum glucose levels were associated with increased mortality in all patients (P for trend \<0.001). Compared with patients with normal serum glucose concentrations (4-5.99 mmol/L), mortality within 90 days increased in a stepwise manner in those with glucose concentrations of 6-10.99 mmol/L (crude hazard ratio 2.89, 95% confidence interval 2.27 to 3.69), 11-13.99 mmol/L (4.01, 2.78 to 5.81), and ≥14 mmol/L (6.04, 4.18 to 8.74); fig 1[](#fig1){ref-type="fig"}).

![**Fig 1** Cumulative incidence of death (%) within 90 days in participants with community acquired pneumonia stratified by serum glucose levels on admission overall (n=6016) (top) and without diabetes (n=5141) (bottom). The 875 participants with missing data for serum glucose levels on admission were not included in these calculations for patients at risk](lepp001743.f1_default){#fig1}

Participants without diabetes on admission showed a clear trend towards an increasing mortality after 90 days with higher than normal serum glucose levels on admission. This observation was highly significant (P for trend \<0.001; fig 1).

Participants without diabetes and normal serum glucose levels had the lowest mortality (3%) after 90 days (fig 2[](#fig2){ref-type="fig"}), whereas the mortality rate in those without diabetes but with high serum glucose levels was 10% (adjusted hazard ratio 1.72, 95% confidence interval 1.33 to 2.23) and those with diabetes was 14% (1.88, 1.42 to 2.47). Although the risk of mortality from community acquired pneumonia was significantly higher in patients with than without diabetes, the relation between glucose levels on admission and mortality was not significant in this cohort (P=0.18). Generally, low serum glucose levels (\<4 mmol/L) were not associated with mortality in participants without diabetes (hazard ratio 0.68, 95% confidence interval 0.33 to 1.42).

![**Fig 2** Cumulative incidence of death (%) within 90 days in participants with community acquired pneumonia with and without pre-existing diabetes (top) and without diabetes but stratified according to high or low serum glucose levels on admission (bottom)](lepp001743.f2_default){#fig2}

The association between hyperglycaemia on admission and mortality was also evident up to day 28. Participants with increased serum glucose levels on admission were more likely to die within the first 28 days after admission than those with normal serum glucose levels (adjusted P for trend \<0.001). Supplementary table 1A shows that participants with diabetes had a higher 28 day mortality than those without diabetes (P=0.042). Compared with participants with normal serum glucose levels and without pre-existing diabetes, the adjusted hazard ratio for death within 28 days after admission in those with diabetes was 1.92 (95% confidence interval 1.34 to 2.75) and in those with hyperglycaemia without diabetes was 1.71 (1.22 to 2.40; P for trend 0.001). The same applied to 90 day mortality for the previously used cut-offs for increased fasting and the cut-offs for increased post-prandial serum glucose levels (see supplementary table 2). Table 2[](#tbl2){ref-type="table"} summarises the multivariable hazard ratios of overall mortality in participants with and without diabetes. Analyses of mortality up to 28 days and up to 180 days showed the same associations with serum glucose levels as the main analyses of 90 day mortality (see supplementary tables 1A-C).

###### 

 Mortality after 90 days, comorbidities, and baseline characteristics of participants with and without diabetes mellitus (n=6870)

  Variables                            No/Total No (%)                   Hazard ratio\* (95% CI)   P value†                                          
  ------------------------------------ ----------------- --------------- ------------------------- ------------------------ ------------------------ ---------
  Sex:                                                                                                                                               
   Women                               76/446 (17)       172/2629 (7)                              1.00 (ref)               1.00 (ref)               0.60
   Men                                 133/668 (20)      307/3127 (10)                             0.97 (0.70 to 1.35)      0.79 (0.63 to 0.99)      
  CRB-65 score‡:                                                                                                                                     
   0                                   4/176 (2)         44/2281 (2)                               1.00 (ref)               1.00 (ref)               0.20
   1                                   82/519 (16)       159/1993 (8)                              4.93 (1.73 to 14.06)     3.74 (2.40 to 5.82)      
   2                                   69/255 (27)       153/691 (22)                              7.87 (2.75 to 22.51)     8.19 (5.16 to 13.01)     
   3                                   24/51 (47)        52/144 (36)                               14.95 (4.85 to 46.03)    14.22 (8.40 to 24.09)    
   4                                   7/8 (88)          10/15 (67)                                31.01 (7.67 to 125.37)   24.37 (10.80 to 54.99)   
  Serum glucose level (mmol/L):                                                                                                                      
   \<4                                 10/40 (25)        10/443 (2)                                1.63 (0.65 to 4.07)      0.68 (0.33 to 1.42)      \<0.001
   4-5.99                              15/99 (15)        116/2141 (5)                              1.00 (ref)               1.00 (ref)               
   6-10.99                             99/505 (20)       268/2254 (12)                             1.28 (0.66 to 2.46)      1.55 (1.18 to 2.04)      
   11-13.99                            35/197 (18)       21/106 (20)                               0.88 (0.42 to 1.84)      2.11 (1.22 to 3.64)      
   ≥14                                 39/182 (21)       11/33 (33)                                1.49 (0.72 to 3.09)      3.65 (1.84 to 7.23)      
  Chronic respiratory tract disease:                                                                                                                 
   No                                  121/628 (19)      283/3761 (8)                              1.00 (ref)               1.00 (ref)               0.67
   Yes                                 86/483 (18)       194/1979 (10)                             0.99 (0.71 to 1.39)      0.94 (0.75 to 1.17)      
  Malignant tumour:                                                                                                                                  
   No                                  174/986 (18)      375/5207 (7)                              1.00 (ref)               1.00 (ref)               0.19
   Yes                                 34/126 (27)       97/521 (19)                               1.24 (0.79 to 1.94)      1.87 (1.43 to 2.44)      
  Chronic liver disease:                                                                                                                             
   No                                  194/1069 (18)     450/5570 (8)                              1.00 (ref)               1.00 (ref)               0.10
   Yes                                 14/42 (33)        29/172 (17)                               2.31 (1.26 to 4.25)      1.23 (0.75 to 2.01)      
  Congestive heart failure:                                                                                                                          
   No                                  95/669 (14)       286/4924 (6)                              1.00 (ref)               1.00 (ref)               0.07
   Yes                                 114/444 (25)      190/817 (23)                              1.22 (0.86 to 1.71)      1.77 (1.41 to 2.23)      
  Cerebrovascular disease:                                                                                                                           
   No                                  117/873 (13)      337/5263 (6)                              1.00 (ref)               1.00 (ref)               0.72
   Yes                                 89/233 (38)       141/485 (29)                              2.07 (1.47 to 2.91)      1.92 (1.49 to 2.46)      
  Chronic renal disease:                                                                                                                             
   No                                  128/886 (14)      390/5402 (7)                              1.00 (ref)               1.00 (ref)               0.88
   Yes                                 79/222 (36)       87/342 (25)                               1.71 (1.21 to 2.44)      1.54 (1.17 to 2.03)      
  Current smoking:                                                                                                                                   
   No                                  149/823 (18)      329/3822 (9)                              1.00 (ref)               1.00 (ref)               0.43
   Yes                                 31/236 (13)       105/1832 (6)                              1.05 (0.66 to 1.66)      0.87 (0.65 to 1.16)      

Row percentages may not total 100% because of missing data.

\*Derived from Cox proportional hazards models after multiple imputation of missing covariate data for participants with and without diabetes mellitus. Hazard ratios larger than 1 indicate a lower mortality in reference category.

†P values for interaction between hazard ratios of death or linear trends across glucose and CRB-65 categories and diabetes status are from two sided Wald tests from interaction terms included in Cox proportional hazards models.

‡Score related to confusion, respiratory rate \>30/min, systolic blood pressure ≤90 mm Hg or diastolic blood pressure ≤60 mm Hg, and age ≥65 years.

Mortality in participants with diabetes
---------------------------------------

Estimates for the cumulative incidence of death within 90 days were significantly higher in participants with than without diabetes (P\<0.001). After adjustment for baseline covariates, overall mortality was significantly higher in participants with diabetes (adjusted hazard ratio 1.26, 95% confidence interval 1.04 to 1.54; P=0.022). The adjusted hazard ratio for mortality up to 28 days was 1.29 (95% confidence interval 1.01 to 1.65; P\<0.001) and up to 180 days was 1.29 (1.08 to 1.54, see supplementary tables 1A-C). Figure 3[](#fig3){ref-type="fig"} shows a higher mortality in participants with diabetes, regardless of serum glucose level on admission, and without diabetes with high serum glucose levels (≥6 mmol/L) on admission. Increases in mortality appeared higher in participants with diabetes in crude analyses but of a similar magnitude in adjusted analyses.

![**Fig 3** Crude and adjusted analyses of cohorts with the highest mortality. Results from all 6891 participants after multiple imputation](lepp001743.f3_default){#fig3}

CRB-65 and serum glucose levels on admission
--------------------------------------------

In an analysis stratified according to CRB-65 score as a measure of pneumonia severity, serum glucose levels were associated with mortality in participants with a low CRB-65 score (0 points, see supplementary figure 3A) and moderate scores (1 or 2 points, see supplementary figure 3B), but not in those with high scores (3 or 4 points, see supplementary figure 3C). Tests for interaction between trends across serum glucose levels and severity of pneumonia and association with serum glucose levels were borderline positive (see supplementary table 3 for the corresponding hazard ratios across serum glucose levels).

Landmark analysis
-----------------

Supplementary table 4 and figure 4 present the results from landmark analyses with a cut-off at 28 days. The association of mortality with serum glucose levels was driven by short term mortality up to 28 days, with statistical trends observed for corresponding P values for interaction with time (0 to 28 days *v* 29 to 90 days).

Examination of data missingness
-------------------------------

Overall, 509 of 7400 participants (6.8%) were excluded from the analysis owing to missing information on vital status. Such participants tended to have a higher CRB-65 score (36% scored 0 or 1 *v* 72% in complete cases), and a higher proportion had diabetes (26% *v* 16%), congestive heart failure (31% *v* 18%), and cerebrovascular disease (35% *v* 10%) compared with those with complete information on mortality (see supplementary table 5). Among the remaining 6891 patients, 875 (12.7%) had no information on serum glucose levels on admission and 21 (0.3%) had no information on baseline diabetes status. Information on CRB-65 scores was missing for 749 participants (10.9%). Thirty one participants had data missing on chronic respiratory tract disease, 39 on malignant tumour, 33 on chronic liver disease, 30 on congestive heart failure, 29 on cerebrovascular disease, 34 on chronic renal disease, and 163 on smoking status. Differences in missingness according to vital status were found for current smoking (64 (12%) in participants who survived up to 90 days *v* 99 (1.6%) in participants who died) and for serum glucose levels (48 (9%) *v* 827 (13%), respectively). Participants with missing data on current smoking had higher CRB-65 scores (P\<0.001) and a shorter survival time (P\<0.001), whereas the opposite was found for serum glucose levels (P\<0.001 and P=0.046, respectively). Complete datasets to assess the severity of community acquired pneumonia by calculating severity scores (CRB-65) were available for 6142 of the participants (89%), and severity of community acquired pneumonia was distributed: 40% with 0 points, 41% with 1 point, 15.5% with 2 points, 3.2% with 3 points, and 0.3% with 4 points. Overall mortality on day 90 was 7.5%.

In total, 5231 (71%) participants had complete data on covariates. Supplementary table 6 compares these participants with those with incomplete data on covariates. Supplementary table 7 reports results of a complete case analysis in these 5231 participants.

Discussion
==========

Mild to moderate hyperglycaemia on admission to hospital (serum glucose concentration 6-10.99 mmol/L; 108-198 mg/dL) has a major impact on mortality at 90 days in patients with community acquired pneumonia and pre-existing diabetes. We also found that patients with diabetes are at increased risk of death within 90 days regardless of their serum glucose levels on admission, and that most of the deaths occurred early and the association with glucose levels was driven by short term mortality up to 28 days. Our results suggest that acute dysregulation of glucose metabolism as well as longstanding diabetes have an impact on death from community acquired pneumonia.

A total of 1114 participants (16.2%) in our population had pre-existing diabetes. This proportion of people with diabetes in a cohort of patients with community acquired pneumonia is in accordance with previous reports on comorbid conditions in such patients, reporting a prevalence of diabetes of 6-25%.[@ref2] [@ref5] [@ref16] In our cohort, hyperglycaemia was identified as an independent factor for increased risk of death from pneumonia. Our study shows that patients without known diabetes and mild to moderately increased serum glucose concentrations (≥6.0 mmol/L) are at an increased risk of death from pneumonia. Although a previous, noticeably smaller study could not detect effects on inhospital mortality at glucose concentrations greater than 6.11 mmol/L to 11.00 mmol/L, and 14.00 mmol/L or more (higher odds ratio for inhospital mortality for patients with serum glucose concentrations between 11.01 and 13.99 mmol/L; P=0.05),[@ref17] our study is the first to show consistently significantly increased hazard ratios in a stepwise manner for mortality at three time points (days 28, 90, and 180) and for serum glucose concentrations of 6.0 mmol/L or more.

When participants were stratified according to serum glucose levels on admission, there was a significant (P\<0.001) and stepwise increasing difference in mortality. Again, in the cohort of participants presenting with baseline serum glucose concentrations of 6.0-10.99 mmol/L the hazard ratio was already 1.56 (95% confidence interval 1.22 to 2.01; P\<0.001) and increased to 2.37 (1.62 to 3.46; P\<0.001) in those with baseline serum glucose concentrations of 14.00 mmol/L or more. We analysed the influence of diabetes on 90 day mortality and found almost a twofold increase in mortality in participants with pre-existing diabetes (adjusted hazard ratio 1.88; P\<0.001).

Hyperglycaemia was associated with mortality in the overall analysis. In an exploratory analysis stratified according to severity of pneumonia using the CRB-65 score, we found associations of serum glucose levels with mortality to be robust for patients with mild or moderate pneumonia (CRB-65 score ≤2) but not for patients with severe pneumonia. Tests for interaction of borderline significance suggested that this variation with severity of pneumonia was over and above that expected by chance alone. There was little evidence to suggest that serum glucose level on admission was associated with mortality in patients with pre-existing diabetes. Serum glucose concentrations below 4 mmol/L (72 mg/dL) were not associated with increased mortality.

Strengths and weaknesses of the study
-------------------------------------

Our study has a prospective design and is possibly the largest cohort on community acquired pneumonia worldwide. This multicentre cohort study in different centres throughout Germany, Switzerland, and Austria, used a highly standardised reporting system and databank. For this study, private practices as well as large tertiary referral centres specialised in the treatment of respiratory tract disorders cooperated closely in patient recruitment. Thus we believe our cohort to be representative of patients with community acquired pneumonia in more economically developed countries. Other studies on glycaemia in patients with community acquired pneumonia used data from patient records in a retrospective manner or derived the diagnosis of community acquired pneumonia from *International Classification of Diseases* coding, which might have resulted in bias.[@ref2] [@ref16] [@ref25]

Our study has several limitations. Firstly, we did not establish a causal relation between serum glucose levels on admission and mortality. It is conceivable that hyperglycaemia is associated with increased mortality, but it is also conceivable that a common factor is related to both hyperglycaemia and increased mortality.

Secondly, there was no structured protocol describing treatment modalities for patients with increased serum glucose levels, and treatment was left to the discretion of the doctor in charge. Hence we were not able to examine changes in serum glucose levels during admission to hospital in a standardised fashion. This might bias results in any direction as we do not know if correction of increased serum glucose levels in community acquired pneumonia is relevant, and if correction is time sensitive. A decade ago, data from surgical patients in intensive care suggested that tight control of glycaemia contributes to a better outcome.[@ref26] However, the same group found that for medical patients this was true only for selected individuals. Unfortunately, these patients could not be identified before treatment.[@ref27] As of today, there is compelling evidence that tight glycaemic control at least in patients with sepsis has no benefit[@ref28] [@ref29] as mortality remains unchanged and patients are at risk of sustaining relevant hypoglycaemia.[@ref30] [@ref31] [@ref32] Definite recommendations on serum glucose levels are lacking.

Additionally, glucocorticoids administered in the initial, acute phase of community acquired pneumonia were not recorded in our study and therefore could not be accounted for in the analysis. However, the use of glucocorticoids in community acquired pneumonia is discouraged in current guidelines and was likely to be low in our study. Continued therapy with corticosteroids of more than 20 mg daily for longer than 14 days was an exclusion criterion.

Thirdly, although diabetes itself is clearly defined, we faced the problem of identifying participants with undiagnosed diabetes and those with stress related hyperglycaemia. Determination of glycated haemoglobin (HbA~1c~) level on admission could have solved this problem only in part, as HbA~1c~ tests and their interpretation were not standardised before 2009. Since 2009, HbA~1c~ testing has been recommended for the diagnosis of type 2 diabetes.[@ref33] [@ref34] Recent studies on community acquired pneumonia reported a prevalence of diabetes of 6-25%, which is in the range of the prevalence of 16% in our cohort.[@ref2] [@ref5] [@ref16] [@ref35] As we were unable to formally determine the robustness of results for a more reliable diagnosis of diabetes by laboratory tests, we cannot exclude the fact that some patients were misclassified. However, in a recent cohort study of patients with critical illness,[@ref36] only about 3% of those with increased serum glucose levels on admission were diagnosed as having type 2 diabetes during the first two years after critical illness. Assuming an equally low extent of diagnostic reclassification of patients through the use of additional laboratory tests in our study, we deem it unlikely that misclassification had an important impact on our results. The clinical definition of diabetes (self report, drug use, including long term use of glucose lowering drugs, or a combination of both), similar to that used by the Emerging Risk Factors Collaboration,[@ref3] seemed the most feasible approach in our setting given the uncertainties associated with the diagnosis of type 2 diabetes in patients with acute infection.

Finally, we had to exclude 509 of the 7400 patients (6.8%) owing to missing information on vital status. Such patients tended to have a higher CRB-65 score and a higher proportion had diabetes, congestive heart failure, or cerebrovascular disease at baseline compared with those with complete information. These differences may have led to bias in both directions, towards an overestimation or underestimation of the association of serum glucose levels with mortality. In addition, information on serum glucose levels on admission was lacking in 12.6% of patients and we attempted to account for this by using multiple imputation. Multiple imputation yields valid results under the condition that there are no systematic differences between the missing values and the observed values (missing completely at random) or if systematic differences between missing and observed values can be explained by differences in observed data (missing at random).[@ref24] Observed patterns of data missingness, their association with baseline characteristics and mortality, and the inclusion of all relevant baseline covariates and variables of vital status in our imputation model make the missing at random assumption plausible.[@ref24] Results from complete case analyses and multiple imputation were similar, with associations being somewhat more conservative after multiple imputation. Furthermore, we found evidence for differences in missingness according to mortality for smoking status and serum glucose levels. Since we included mortality variables in the imputation model, this is unlikely to have invalidated our results. Additional limitations include potential residual confounding despite adjustment, and the possibility of a type II error in participants with diabetes: the number of such participants may have been too low to detect an association of serum glucose levels with mortality in this subgroup.

Comparison with other studies
-----------------------------

The CAPNETZ cohort includes outpatients and a greater proportion of patients with mild pneumonia than does other cohorts. The mean age of patients in the present cohort was 60 years, which is lower than in most other cohorts on community acquired pneumonia. Furthermore, the admission rate to intensive care was relatively low, again reflecting a high proportion of mild cases. As severe hypoglycaemia tends to occur in patients who are critically ill, this may explain the lack of association of hypoglycaemia with mortality in our study compared with other studies.[@ref25] [@ref37]

In line with our findings, data from a small trial in a veteran population with pneumococcal pneumonia suggest that hyperglycaemia is associated with greater disease severity and a worse outcome in patients without diabetes; however, this finding could not be extended to people with diabetes.[@ref18]

Our results are consistent with and extend the findings of another retrospective analysis of unselected inpatients.[@ref38] In this study, groups were stratified according to whether participants had normoglycaemia, pre-existing diabetes, or newly diagnosed hyperglycaemia (fasting serum glucose concentration \>7 mmol/L or random serum glucose concentration \>11.1 mmol/L on two separate occasions). Compared with patients with normoglycaemia, after adjustment for important confounding factors, mortality was almost 20 times higher in patients with newly diagnosed hyperglycaemia (P\<0.05), but only 2.7 times higher in those with known diabetes (P\<0.05). As in the present study, it was not possible to distinguish between new onset diabetes and transient stress hyperglycaemia.[@ref38] The higher mortality observed in patients with community acquired pneumonia with diabetes may be due to the worsening of pre-existing cardiovascular disease or higher risk of acute kidney injury, thus a result of comorbidities that are more likely to be present in patients with longstanding diabetes. Patients with diabetes might in part be protected from acute glucose toxicity.[@ref39] [@ref40]

Additionally, our results support data from two Danish population based studies.[@ref2] [@ref16] The first study reported a higher risk of hospital admission in hyperglycaemic patients with community acquired pneumonia and diabetes.[@ref2] Unfortunately the effects in patients without diabetes were not assessed. A second study from the same group found a higher mortality in hyperglycaemic patients without diabetes at 30 days.[@ref16]

Our findings are in contrast with those of a recent study, which found that serum glucose levels on admission were associated with neither an increased risk of mortality at 90 days or death at one year.[@ref12] However, the authors concluded that increased serum glucose levels on admission might be harmful, as their estimate of 90 day mortality associated with the highest dysglycaemic category was non-significantly increased. We assume the sample size of this study to be too small to detect significant differences between groups.

Explanations
------------

In the past, stress hyperglycaemia was often thought to be a useful adaptive response, glucose being a ready source of fuel for brain, skeletal muscle, heart, and other organs at a time of increased metabolic demand. Our results show that hyperglycaemia on admission in patients with community acquired pneumonia is associated with an adverse outcome and predicts mortality. This is the largest prospective cohort trial in patients with community acquired pneumonia on this topic, supporting and extending data from previous, smaller studies or retrospective, population based observational studies that showed an association of hyperglycaemia on admission with adverse events in the course of disease.[@ref2] [@ref11] [@ref13] [@ref14] [@ref16] [@ref17] [@ref25] Our data clearly show by severity adjusted multivariate analysis that increased serum glucose levels at admission is a risk factor for increased risk of mortality in patients with community acquired pneumonia and that mortality starts to increase when serum glucose levels are slightly increased but remain below the defined threshold for overt diabetes.

Conclusions and clinical implications
-------------------------------------

From our data we assume that patients with increased serum glucose levels or diabetes at the time community acquired pneumonia is diagnosed are at significantly increased risk of death from the disease. Oral glucose tolerance test and close glucose monitoring after discharge are necessary to diagnose overt diabetes and to prevent subacute or long term complications. Large scale trials are needed to define optimal serum glucose levels and to determine if a drug intervention is suitable to reduce mortality in patients with community acquired pneumonia. A focus on patients with a CRB-65 score of 2 or less seems most promising, as the evidence for an association of serum glucose levels with mortality was particularly robust in these patients.

### What is already known on this topic

1.  One of the leading infectious diseases in more economically developed countries, community acquired pneumonia, is associated with considerable morbidity and mortality

2.  Hyperglycaemia is a risk factor for premature death from different causes, including infectious diseases

3.  Previous, mainly small and retrospective studies found an association between hyperglycaemia and death from community acquired pneumonia

### What this study adds

1.  Mild to moderate hyperglycaemia on admission to hospital has a major impact on mortality in patients with community acquired pneumonia and previously undiagnosed diabetes

2.  Patients with diabetes are at increased risk of death regardless of serum glucose levels on admission

3.  Acute dysregulation of glucose metabolism as well as longstanding diabetes may have an impact on mortality in patients with community acquired pneumonia
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